Tag: fund

Las Vegas, Nevada, June 08, 2026 (GLOBE NEWSWIRE) -- Primior Holdings Inc. (OTCMKT: PTKN) today announced financial results for the quarter ended March 31, 2026, highlighted by revenue growth, profitability, and continued expansion of the Gaia Marketplace ecosystem. Primior continues to execute on its strategy of integrating real estate, capital markets, and tokenization into a unified platform designed to create long-term shareholder value.

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Proceeds fully fund the company through 2028 and will be used to accelerate commercialization of Solidion’s patented Extreme-Climate Battery Technology targeting the Lunar economy and
space applications

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.